These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11086205)

  • 21. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
    Smit EF; van Meerbeeck JP; Lianes P; Debruyne C; Legrand C; Schramel F; Smit H; Gaafar R; Biesma B; Manegold C; Neymark N; Giaccone G;
    J Clin Oncol; 2003 Nov; 21(21):3909-17. PubMed ID: 14581415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
    Scagliotti GV; Park K; Patil S; Rolski J; Goksel T; Martins R; Gans SJ; Visseren-Grul C; Peterson P
    Eur J Cancer; 2009 Sep; 45(13):2298-303. PubMed ID: 19473833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
    Antón A; Díaz-Fernández N; González Larriba JL; Vadell C; Masutti B; Montalar J; Barneto I; Artal A; Rosell R
    Lung Cancer; 1998 Nov; 22(2):139-48. PubMed ID: 10022221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Kocijancic I; Segedin B; Vrankar M
    Anticancer Drugs; 2005 Nov; 16(10):1129-34. PubMed ID: 16222156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
    Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
    Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.
    Brodowicz T; Krzakowski M; Zwitter M; Tzekova V; Ramlau R; Ghilezan N; Ciuleanu T; Cucevic B; Gyurkovits K; Ulsperger E; Jassem J; Grgic M; Saip P; Szilasi M; Wiltschke C; Wagnerova M; Oskina N; Soldatenkova V; Zielinski C; Wenczl M;
    Lung Cancer; 2006 May; 52(2):155-63. PubMed ID: 16569462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High COL4A3 expression correlates with poor prognosis after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
    Jiang CP; Wu BH; Chen SP; Fu MY; Yang M; Liu F; Wang BQ
    Tumour Biol; 2013 Feb; 34(1):415-20. PubMed ID: 23108892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis.
    Ma D; Wang J; Hao X; Wang Y; Hu X; Xing P; Li J
    Thorac Cancer; 2017 Sep; 8(5):482-488. PubMed ID: 28745824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
    Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
    Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
    Gatzemeier U; Pluzanska A; Szczesna A; Kaukel E; Roubec J; De Rosa F; Milanowski J; Karnicka-Mlodkowski H; Pesek M; Serwatowski P; Ramlau R; Janaskova T; Vansteenkiste J; Strausz J; Manikhas GM; Von Pawel J
    J Clin Oncol; 2007 Apr; 25(12):1545-52. PubMed ID: 17442998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness of gemcitabine in combination with cisplatin in a randomized study of untreated patients with advanced non-small-cell lung carcinoma].
    Mehić B; Zutić H; Dizdarević Z; Lomigorić J
    Med Arh; 2004; 58(1):11-3. PubMed ID: 15017896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial.
    Zwitter M; Kovac V; Rajer M; Vrankar M; Smrdel U
    Anticancer Drugs; 2010 Jul; 21(6):662-8. PubMed ID: 20453635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
    Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer.
    Abratt RP; Bezwoda WR; Goedhals L; Hacking DJ
    J Clin Oncol; 1997 Feb; 15(2):744-9. PubMed ID: 9053500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
    Grossi F; de Marinis F; Gebbia V; Riccardi F; Caffo O; Gamucci T; Ferraù F; Nardi M; Moscetti L; Boni L; Dondi D; Galligioni E
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):369-75. PubMed ID: 21833588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.